Case Control Study
Copyright ©The Author(s) 2024.
World J Diabetes. Aug 15, 2024; 15(8): 1717-1725
Published online Aug 15, 2024. doi: 10.4239/wjd.v15.i8.1717
Table 1 Demographic characteristics by insulin dependence, mean ± SD
Variable
Total (n = 132)
No insulin dependence (n = 64)
Insulin dependence (n = 68)
P value
Sex (M) (%)71 (53.8)34 (53.1)37 (54.4)0.51
Age (years)15.9 ± 1.315.98 ± 1.315.9 ± 1.40.85
Weight (kg)73.4 ± 10.172.2 ± 10.474.5 ± 9.80.06
Height (cm)165.3 ± 6.4164.7 ± 6.5165.9 ± 6.30.11
BMI (kg/m2)25.2 ± 3.524.9 ± 3.825.5 ± 3.10.09
BMI z-score1.39 ± 0.441.35 ± 0.461.43 ± 0.410.42
WC (cm)87.4 ± 9.985.1 ± 10.689.1 ± 8.90.22
WHtR0.52 ± 0.050.52 ± 0.060.53 ± 0.040.08
SBP (mm/Hg)111.6 ± 11.2110.3 ± 10.7112.9 ± 11.60.05
DBP (mm/Hg)72.0 ± 8.570.6 ± 7.873.3 ± 9.00.1
DD (years)4.49 ± 0.884.73 ± 0.094.27 ± 0.700.03
Table 2 Metabolic characteristics by insulin dependence, mean ± SD
Variable
Total (n = 132)
No insulin dependence (n = 64)
Insulin dependence (n = 68)
P value
TC (mg/dL)175.9 ± 48.3164.2 ± 37.4186.9 ± 54.80.54
HDL-C (mg/dL)44.1 ± 9.344.6 ± 7.543.6 ± 10.80.11
LDL-C (mg/dL)107.1 ± 41.193.3 ± 28.8118.3 ± 47.50.1
TG (mg/dL)158.5 ± 21.1148.5 ± 14.0187.9 ± 19.90.18
Fasting glucose (mmol/L)10.95 ± 0.557.62 ± 0.3714.07 ± 0.510.08
HbA1c (%)8.8 ± 2.96.7 ± 1.610.8 ± 2.30.001
Insulin (mUI/mL)11.4 ± 7.712.7 ± 9.610.3 ± 5.00.3
C- peptide (ng/dL)1.4 ± 1.32.53 ± 1.20.41 ± 0.360.001
HOMA-β85.38 ± 16.6125.5 ± 15.650.9 ± 16.80.022
Table 3 Demographic characteristics by autoimmunity
VariableAt the time of diagnosis
NID
P value
At the time of diagnosis
ID
P value
NID (n = 64)
(Ab+) (n = 16)
(Ab-) (n = 48)
ID (n = 68)
(Ab+) (n = 27)
(A-) (n = 41)
Sex (F) (%)8 (50.0)26 (54.1)0.7716 (59.2)21 (51.2)0.51
Age (years)12.9 ± 0.715.9 ± 1.416.0 ± 1.30.8713.1 ± 0.916.1 ± 1.415.7 ± 1.40.3
Weight (kg)68.9 ± 13.967.2 ± 11.273.9 ± 9.60.0474.6 ± 10.573.6 ± 8.475.0 ± 10.60.57
Height (cm)159.2 ± 6.0161.7 ± 7.6165.7 ± 5.90.03162.2 ± 5.96165.9 ± 6.2166.0 ± 6.50.95
BMI (kg/m2)26.0 ± 5.024.8 ± 3.325.0 ± 4.00.8126.6 ± 4.225.6 ± 2.525.4 ± 3.50.85
BMI z-score 1.61 ± 0.61.25 ± 0.41.38 ± 0.40.311.68 ± 0.41.40 ± 0.31.46 ± 0.40.52
WC (cm)92.6 ± 9.485.9 ± 9.585.1 ± 11.10.9194.6 ± 10.889.0 ± 7.189.1 ± 10.00.95
WHtR (cm)0.56 ± 0.060.53 ± 0.050.51 ± 0.070.470.56 ± 0.060.53 ± 0.030.53 ± 0.500.94
SBP (mmHg)112 ± 12.2109.8 ± 10.0110.5 ± 11.00.8218 ± 14.6112.3 ± 13.2113.2 ± 10.60.75
DBP (mmHg)74.5 ± 8.470.7 ± 7.070.6 ± 8.10.9678.8 ± 9.273.1 ± 10.273.5 ± 8.20.86
DD (years)4.76 ± 0.954.72 ± 0.090.874.38 ± 0.824.19 ± 0.730.34
Table 4 Metabolic characteristics of the groups by autoimmunity
VariableAt the time of diagnosis
NID
P value
At the time of diagnosis
ID
P value
NID (n = 64)
Ab+) (n = 16)
(Ab-) (n = 48)
ID (n = 68)
(Ab+) (n = 27)
(A-) (n = 41)
TC (mg/dL)164.8 ± 39170 ± 32.9162.1 ± 38.80.44170 ± 37.5189.2 ± 60.7185.3 ± 51.30.77
HDL-C (mg/dL)41.9 ± 11.445.8 ± 6.944.1 ± 7.70.4243.6 ± 8.042.2 ± 8.044.5 ± 12.40.39
LDL-C (mg/dL)97.9 ± 3096.8 ± 23.294.8 ± 30.60.8296.2 ± 29.3124.8 ± 51.6114.0 ± 44.80.38
TG (mg/dL)136.4 ± 28162.5 ± 21.1143.8 ± 11.00.65153.3 ± 22172.6 ± 9.8164.8 ± 10.90.75
Glucose (mmol/L)14.77 ± 2.167.58 ± 2.937.64 ± 3.970.9613.27 ± 2.5513.66 ± 0.5414.68 ± 0.250.43
HbA1c (%)9.7 ± 2.76.8 ± 1.86.3 ± 0.90.919.2 ± 2.211.4 ± 2.610.4 ± 2.10.09
Insulin (mUI/mL)16.7 ± 1.69.3 ± 4.813.8 ± 9.50.0221.1 ± 2.89.5 ± 3.710.7 ± 5.70.04
C-peptide (ng/mL)0.3 ± 0.092.3 ± 1.22.6 ± 1.20.421.1 ± 0.260.30 ± 0.250.40 ± 0.040.19
HOMA-β72.3 ± 33.964.8 ± 45.3125.7 ± 15.80.0291.5 ± 30.625.8 ± 34.661.3 ± 20.20.02
Table 5 Frequency of antibody positivity, n (%)
Variable
Total (n = 132)
No insulin dependence (n = 64)
Insulin dependent (n = 68)
P value
Anti-GAD 6539 (29.5)13 (20.3)26 (38.2)0.02
Anti-IA224 (18.2)8 (12.5)16 (23.5)0.07
Anti-Zn8T21 (15.9)3 (4.7)18 (26.5)0
Anti-GAD65 + anti-IA220 (15.2)5 (7.8)15 (22.1)0.02
Anti-GAD65 + anti-Zn8T15 (11.4)3 (4.7)12 (17.6)0.01
Anti-IA2 + anti-Zn8T12 (9.1)2 (3.1)10 (14.7)0.02
Three antibodies12 (9.1)2 (3.1)10 (14.7)0.02
Table 6 Antibody titers according to insulin dependence
Variable
Total (n = 132)
No insulin dependence (n = 64)
Insulin dependent (n = 68)
P value
Anti-GAD65 (UI/mL)11.0 (5-543)6.8 (5-543)12.0 (5-186)0.69
Anti-IA2 (UI/mL)14.6 (5-245)8.45 (5-111)21.6 (5-245)0.6
Anti-Zn8T (UI/mL)68.5 (15.9-178.2)64.5 (47-74.5)73.7 (15.9-178.2)0.68
Table 7 Estimation of risks according to antibodies
Variable
Odds ratio early insulin requirements (n = 132)
OR adj (95%CI)
P value
Anti-GAD652.42 (1.112- 5.303)0.026
Anti-IA21.55 (0.859- 2.818)0.101
Anti-Zn8T7.32 (2.039-26.279)0.002
Anti-GAD65 + Anti-IA23.34 (1.136- 9.814)0.028
Anti-GAD65 + anti-Zn8T4.35 (1.168-16.248)0.028
Anti-IA2 + anti-Zn8T5.34 (1.123-25.431)0.035
Anti-GAD65 + Anti-IA2 + anti-Zn8T5.34 (1.123-25.431)0.035